Short synthetic CDR-peptides forming the antibody combining site of the monoclonal antibody against RNA bacteriophage fr neutralize the phage activity

Human Antibodies

Volumn 7, Issue 3, 1996, Pages 106-112

  Steinbergs, Juris ^a   Kilchewska, Katarzina ^a   Lazdina, Una ^a   Dishlers, Andris ^a   Ose, Velta ^a   Sällberg, Matti ^b   Tsimanis, Alexander ^a  

^a UNIVERSITY OF LATVIA   (Latvia)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Monoclonal antibody; Phage neutralization; RNA phage; Synthetic CDR peptide

Indexed keywords

MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; SYNTHETIC PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY COMBINING SITE; ANTIBODY STRUCTURE; ANTIVIRAL ACTIVITY; ARTICLE; BACTERIOPHAGE; CONTROLLED STUDY; HYBRIDOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; BASE SEQUENCE; CLONING, MOLECULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; IMMUNOGLOBULIN VARIABLE REGION; MICE; MICE, INBRED BALB C; MICROSCOPY, IMMUNOELECTRON; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; PEPTIDE FRAGMENTS; RNA PHAGES;

EID: 0030512903     PISSN: 10932607     EISSN: 1875869X     Source Type: Journal    
DOI: 10.3233/HAB-1996-7303     Document Type: Article

References (24)

1. Fiers W. Structure and function of RNA bacteriophages. In: Fraenkel-Conrat H, Wagner RR, eds. Comprehensive Virology, vol 13, New York: Plenum Publishing Corp, 1979
2. Van Duin J. Single-stranded RNA bacteriophages. In: Calendar R, ed. The Bacteriophages, New York: Plenum Press, 1988
3. Golmohammadi R, Valergard K, Fridborg K, Liljas L. The refined structure of bacteriophage MS2 at 2.8 A resolution.J Mol Biol 1993; 234: 620
4. Liljas L, Fridborg K, Valegard K, Bundule M, Pumpen P. Crystal structure of bacteriophage fr capsids at 3.5 A resolution. J Mol Biol 1994; 244: 279
5. Rohrmann GF, Krueger RG. Physical, biochemical and immunological properties of coliphage MS2 particles. J Immunol 1970; 104: 353
6. Scott DW. Serological cross-reactions among the RNA-containing coliphage. Virology 1965; 26: 85
7. Harigai H, Furuse K, Inokuchi Y, Hirashima A. Characterization of an intergroup serological mutant from group II RNA phage GA. Microbiol Immunol 1986; 30: 1247
8. Langbeheim H, Arnon R, Sela M. Antiviral effect on MS-2 coliphage obtained with a synthetic antigen. Proc Natl Acad Sci USA 1976; 73: 4636
9. Van Assche W, Vanderkerckhove J, Van Montagu M. Mutation sites in the coat-protein gene of bacteriophage MS2. Arch Int Physiol Biochem 1974; 82: 1020
10. Furuse K, Hiraschima A, Harigai H, Ando A, Watanabe K, Kurosawa K, Inokuchi Y, Watanabe I. Grouping of RNA coliphages based on analysis of the sizes of their RNAs and protein. Virology 1979; 97: 328
11. Williams WV, Kieber-Emmons T, VonFeldt J, Greene MI, Weiner DB. Design of bioactive peptides based on antibody hypervariable region structures. J Biol Chem 1991; 266: 5182
12. Saragovi HU, Fitzpatrick D, Raktabutr A, Nakanishi H, Kahn M, Greene M. Design and synthesis of a mometic from an antibody complementarity-determining region. Science 1991; 253: 792
13. Welling GW, van Gorkum J, Damhof RA, Drijfhout JW, Bloemhoff W, Welling-Wester S. A ten-residue fragment of an antibody (mini-antibody) directed against lysozyme as ligand in immunoaffinity chromatography. J Chromatogr 1991; 548: 235
14. Levi M, Sallberg M, Ruden U, Herlyn D, Maruyama H, Wigzell H, Marks J, Wahren B. A complementarity-determining region synthetic peptide acts as a miniantibody and neutralizes human immunodeficiency virus type 1 in vitro. Proc Natl Acad Sci USA 1993; 90: 4373
15. Sivolapenko GB, Douli V, Pectasides D, Skarlos D, Sirmalis G, Hussain R, Cook J, Courtney-Luck NS, Merkouri E, Konstanti-nides K, Epenetos AA. Breast cancer imaging with radiolabeled peptide from complementarity-determining region of antitumour antibody. Lancet 1995; 346: 1662
16. Skrivelis V, Steinberg Yu, Bichko V, Gren E, Tsimanis A. The structure of the variable regions of mouse monoclonal antibodies to hepatitis B virus core antigen. Scand J Immunol 1993; 37: 637
17. Kabat EA, Wu TT, Reid-Miller M, Perry HM, Gottesman KS. Sequences of Proteins of Immunological Interest, 4th edn, US Department of Health and Human Services, Bethesda, MD, 1987
18. Sallberg M, Ruden U, Magnius LO, Norrby E, Warre B. Rapid " tea-bag" peptide synthesis using 9-fluorenylmethoxcarbonyl (Fmoc) protected amino acids applied for antigenic mapping of viral proteins. Immunol Lett 1991; 30: 59
19. Lin JP, Nicholas K, Ball FR, McLaughlin B, Bishai FR. Detection of Norwalk-like virus and specific antibody to immune-electron microscopy with colloidal gold immune complexes. J Virol Methods 1991; 35: 237
20. Orlandi R, Gussow DH, Jones PT, Winter G. Cloning immunoglobulin variable domains for expression by the polymerase chain reaction. Proc Natl Acad Sci USA 1986; 86: 3833
21. Chiang YL, Sheng-Dong R, Brow MA, Larrick JW. Direct cDNA cloning of the rearranged immunoglobulin variable genes. BioTechniques 1989; 7: 360
22. Caton AJ, Stark SE, Kavaler J, Staudt LM, Schwartz D, Gerhard W. Many variable region genes are utilized in the antibody responses of BALB/c mice to the influenza virus A/PR/8/34 hemagglutinin. J Immunol 1991; 147: 1675
23. Clarke SH, Huppi K, Ruezinsky D, Staudt L, Gerhardt W, Weiger M. Inter- and intraclonal diversity in the antibody response to influenza hemagglutinin. J Exp Med 1985; 161: 687
24. Inokuchi Y, Takahashi R, Hirose T, Inayama S, Jacobson AB, Hirashima A. The complete nucleotide sequence of the group II RNA coliphage. J Biochem 1986; 99: 1169